Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.
Document Type
Journal Article
Publication Date
10-20-2019
Journal
Journal of Clinical Oncology
Volume
37
Issue
30
Inclusive Pages
2769-2777
DOI
10.1200/JCO.18.01972
APA Citation
Dix, D. B., Fernandez, C. V., Chi, Y., Mullen, E. A., Geller, J. I., Gratias, E. J., Khanna, G., Kalapurakal, J. A., Perlman, E. J., Seibel, N. L., Ehrlich, P. F., Malogolowkin, M., Anderson, J., Gastier-Foster, J., Shamberger, R. C., Kim, Y., Grundy, P. E., & Dome, J. S. (2019). Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.. Journal of Clinical Oncology, 37 (30). http://dx.doi.org/10.1200/JCO.18.01972
Peer Reviewed
1
